Allergic Transfusion Reaction
Conditions
Keywords
pretransfusion medication, Chlorpheniramine, blood transfusion, allergic transfusion reaction
Brief summary
This is a prospective, randomized, double-blind controlled trial to evaluate the efficacy of placebo versus chlorpheniramine for the prevention of allergic transfusion reactions.
Interventions
DRUGPlacebo
The tablet resembles chlorpheniramine but has no therapeutic value.
DRUGChlorpheniramine
An antihistamine that reduces the natural chemical histamine in the body.
Sponsors
Institute of Hematology & Blood Diseases Hospital, China
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Masking description
Neither patients nor medical staff, including physicians and nurses participating in this study, will know the group assignment after allocation.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* 18\ 65 years old. * Subject is diagnosed with hematological disorder and requires blood product (i.e. suspended red blood cells, apheresis platelets, fresh frozen plasma) transfusions. * Subject can fully understand and voluntarily sign informed consent forms.
Exclusion criteria
* Subject with a history of allergic diseases. * Subject experienced at least 1 moderate/severe or 2 mild allergic reactions in the past. * Subject received glucocorticoid or allergy drugs within 24 hours before blood transfusion. * Subject transfused with washed RBC. * Received allo-HSCT transplantation before. * Subject with heart failure. * Subject suffered from sequelae of cardiovascular or cerebrovascular diseases. * Pregnant or nursing women. * Inability to understand or to follow study procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of allergic-transfusion reactions | within 4 hours from the start of the transfusion |
Countries
China
Contacts
Primary ContactJun Shi, PhD
Backup ContactJingyu Zhao, MPH
Outcome results
None listed